Dr. Reddy's Laboratories Ltd. is acquiring a basket of ANDAs from Teva Pharmaceutical Industries Ltd. as it increasingly leans towards developing and building a portfolio of complex and limited competition generics in the US and hopes to become "more relevant" there.
The products being acquired form part of the portfolio that Teva is purging as a precondition to its closing of the $40.5bn acquisition of Allergan PLC’s generics business.
The Hyderabad-based Dr Reddy's said, over the weekend, that it had entered into a definitive agreement with Teva and an...
Create an account to read this article
Already a subscriber?
Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
